AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth CareGeographicals
Parasite LoadParasitesLeishmaniasis, VisceralHost-Parasite InteractionsLeishmania infantumLeishmaniasis, CutaneousParasitic Diseases, AnimalAntiprotozoal AgentsLeishmania majorParasite Egg CountLeishmaniaLeishmaniasis VaccinesLeishmaniasisLeishmania donovaniDNA, ProtozoanPlatyhelminthsTrypanosoma cruziParasitemiaChagas DiseaseProtozoan ProteinsHawksEctoparasitic InfestationsSulfadimethoxineToxoplasmaPlasmodium falciparumMice, Inbred BALB CAntibodies, ProtozoanLeishmania braziliensisMalariaLeishmania mexicanaProtozoan VaccinesAntigens, ProtozoanParasitologyDNA, KinetoplastDog DiseasesMeglumineMalaria, FalciparumChagas CardiomyopathyPoeciliaToxoplasmosis, AnimalCryptosporidiosisPsychodidaeSpleenLizardsFish DiseasesBloodFecesPolymerase Chain ReactionApicomplexaLife Cycle StagesIntestinal Diseases, ParasiticMice, Inbred C57BLSkinPlasmodium bergheiAntimalarialsParasitic DiseasesInterferon-gammaDogsCytokinesDisease Models, AnimalBrazilTrematodaDisease SusceptibilityErythrocytesGenes, ProtozoanReal-Time Polymerase Chain ReactionMesocricetusCestodaProtozoan InfectionsInterleukin-10Protozoan Infections, AnimalMacrophagesHaemosporidaGenome, ProtozoanSensitivity and SpecificityHelminthsHelminthiasis, AnimalGenetic LoadImmunoglobulin GParasitic Sensitivity TestsSchistosoma mansoniLiverSporozoitesDrug ResistanceNematode InfectionsMolecular Sequence DataTh1 CellsPlasmodium yoeliiTrematode InfectionsPlasmodium vivaxChloroquineTrophozoitesTrypanosoma brucei bruceiMice, KnockoutAnophelesAcanthocephalaCricetinaeOocystsSchizontsMerozoites

1NM-PP1 treatment of mice infected with Toxoplasma gondii. (1/207)

Bumped kinase inhibitors (BKIs) target analog-sensitive kinases, which the genomes of mammals rarely encode. Previously, we demonstrated that a BKI effectively suppressed the in vitro replication of Toxoplasma gondii, the causative pathogen of toxoplasmosis, by targeting T. gondii calcium-dependent protein kinase 1 (TgCDPK1) (Eukaryotic Cell, 9: 667-670). Here, we examined whether the BKI 1NM-PP1 reduced parasite replication in vivo. A high dose of 1NM-PP1, by intraperitoneal injection, just before the parasite inoculation effectively reduced the parasite load in the brains, livers, and lungs of T. gondii-infected mice, however, a low dose of 1NM-PP1 with oral administration didn't change the survival rates of infected mice.  (+info)

Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy. (2/207)

 (+info)

Long-term cleaner fish presence affects growth of a coral reef fish. (3/207)

 (+info)

In vitro and in vivo antileishmanial efficacy of a combination therapy of diminazene and artesunate against Leishmania donovani in BALB/c mice. (4/207)

 (+info)

In vitro and in vivo studies of the utility of dimethyl and diethyl carbaporphyrin ketals in treatment of cutaneous leishmaniasis. (5/207)

 (+info)

Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid. (6/207)

 (+info)

Analysis of the expression of toll-like receptors 2 and 4 and cytokine production during experimental Leishmania chagasi infection. (7/207)

 (+info)

Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis. (8/207)

 (+info)